Nanotechnology has caused the most noteworthy influence on oncology,
recently. Many nano-based delivery systems for specific medicines and a diversity of
other diseases are being advanced nowadays. Nanomedicine is preferably adapted to
resolving the main issues of numerous diseases, as it offers the special opportunity to
create specific nanoparticles as a carrier for the targeted and controlled transferal of
several therapeutic agents to the targeted location. Moreover, ligand-targeting or
receptor-mediated targeting methods relate to an extra degree of complexity that may
be implemented in the nanoparticles-based product in cardiovascular diseases. Despite
the noteworthy increase in studies on the use of nanoparticles in cardiovascular disease,
some reports have shown that different types of nanoparticles have cytotoxic action.
Future studies are desired to fully investigate toxicity, especially cytotoxicity and
inflammatory responses for nanomaterials. The outline of new plans to reduce toxicity
should be the aim of future studies. In the present chapter, we emphasize new
developments in cardiovascular nanopharmacology and the assistant methods for
scheming new nanomaterials for this field. The future lookouts have also been
discussed.
Keywords: Cardiovascular diseases, Drug delivery system, Nanotechnology.
